Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Clinical Genitourinary Cancer Année : 2019

Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation

Fichier non déposé

Dates et versions

inserm-02532762 , version 1 (06-04-2020)

Identifiants

Citer

Yana Beulque, Anne-Leen Deleu, Kevin Punie, Liesbeth de Wever, Marcella Baldewijns, et al.. Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. Clinical Genitourinary Cancer, 2019, 17 (5), pp.e909-e912. ⟨10.1016/j.clgc.2019.06.013⟩. ⟨inserm-02532762⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More